Impel co-founder and CSO, Dr. John Hoekman, presented today at 11:00 AM on a panel discussing, "What’s New in Alzheimer’s and Other Neurodegenerative Diseases?" at Life Science Innovation Northwest 2018 in Seattle, WA. The panel was moderated by Dr. Adrian Hobden, President & CEO of CereSpir. Dr. John Hoekman was joined by Dr. Leen Kawas, President & CEO...

Impel's CEO, Jon Congleton, CSO, Dr. John Hoekman, and CMO, Dr. Stephen Shrewsbury, will be presenting at Cowen's 38th Annual Health Care Conference in Boston, MA on Wednesday, March 14th from 1:30 - 1:55 PM EDT. For more information, visit www.cowen.com/capabilities/conferences-events. ...

Novel, Intranasal Dihydroergotamine Dosed via Precision Olfactory Delivery, or POD™, Device Achieved Primary Outcome of Bioavailability, Safety Study Marks First of Four Impel Clinical Trial Read Outs Planned for 2018 SEATTLE, Feb. 7, 2018  -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today...

Impel raises Series B round to commercialize POD technology platform and Impel’s growing portfolio of enhanced CNS products SEATTLE, October 14, 2015 -- Impel NeuroPharma Inc., (Impel) today announced the first close in its Series B financing round to commercialize the company’s revolutionary Precision Olfactory Delivery (POD) technology for the enhanced...

November 15, 2013   Purpose Summary To compare the usability and tolerability of the Impel Precision Olfactory Delivery (POD) device to a reference conventional pump nasal spray device (CNS) in the administration of a saline dose. Background and Objectives The specific objectives of this study were to identify: • How well participants tolerated nasal saline administered by...

November 12, 2013 Purpose: In multiple species, intranasal administration of drug has been shown to bypass the blood-brain-barrier and deliver drugs directly to the central nervous system (CNS). This route of delivery has the potential to enable many therapeutics, including peptide and proteins, to reach the CNS in effective concentrations and could...